Bank of America analysts on Friday said Novo Nordisk may miss first-quarter expectations, as sales of its blockbuster Wegovy ...

The results pave the way for Rybelsus to become a new treatment option for people living with diabetes and established heart ...

The trial results are critical, as it brings Eli Lilly’s pill one step closer to becoming a new, needle-free alternative for ...

Novo Nordisk has defended disappointing trial results for its much-hyped next generation obesity drug candidate CagriSema, insisting it will be an “important” weight loss treatment.

Novo Nordisk has quickly expanded its discounted Wegovy program, now offering all eligible cash-paying customers its popular ...

CHICAGO -- Semaglutide further solidified its efficacy for diabetes-associated cardiovascular conditions, this time building ...

The market has had shortages of semaglutide injection in the past. This has included Wegovy. But it’s important to know that the FDA prioritizes the assessment and development of generic drugs ...

Novo Nordisk’s (NVO) stock has dropped by 25% in March (on the Copenhagen exchange) to put it on track for its biggest ...

Both results wiped significant value from Novo's share price as investors' hopes of finding a superior alternative to the company's existing Wegovy injection and rival Eli Lily's Zepbound ...